Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corporation reports developments in healthcare technology for life sciences marketing, with updates centered on tools that connect pharmaceutical brands with healthcare professionals and patients. The company’s platform uses EHR-based access, omnichannel activation, the Dynamic Audience Activation Platform, and Micro-Neighborhood audiences to support HCP and direct-to-consumer engagement.
Recurring OptimizeRx news includes product and network launches, programmatic access to EHR advertising, privacy-safe identity resolution collaborations, quarterly and annual results, debt and share-repurchase actions, and board or leadership changes. Coverage also reflects the company’s focus on privacy-compliant audience targeting and campaign measurement across healthcare marketing channels.
OptimizeRx (Nasdaq: OPRX) announced management participation in two June 2026 investor conferences. Executives will attend the Stifel 2026 Boston Cross Sector 1x1 Conference on June 2, 2026, in Boston, and William Blair’s 46th Annual Growth Stock Conference on June 3, 2026, in Chicago.
OptimizeRx (Nasdaq: OPRX) announced that DeepIntent will be the first healthcare DSP to integrate its proprietary, authenticated EHR network into a programmatic advertising platform.
The collaboration expands programmatic access to point of care media, enabling life sciences marketers to reach HCPs within clinical workflows, with availability on DeepIntent expected in Q3 2026.
OptimizeRx (Nasdaq: OPRX) reported Q1 2026 revenue of $19.8 million, down 10% year over year. GAAP net loss narrowed to $0.5 million ($0.03 per share). Non-GAAP net income was $2.7 million ($0.14 per diluted share) and adjusted EBITDA reached $3.3 million.
Cash stood at $20.2 million with $23.6 million of debt. The company refinanced into a $35 million Fifth Third Bank facility, expecting about $1.5 million in annual interest savings, and launched efficiency initiatives targeting $3 million annualized savings. 2026 guidance is $95–$100 million revenue and $21–$25 million adjusted EBITDA.
OptimizeRx (Nasdaq: OPRX) launched a new programmatic connection between its proprietary EHR network and demand-side platforms (DSPs), allowing life sciences media buyers to activate authenticated, point-of-care EHR campaigns directly within existing programmatic workflows.
The launch provides access to EHR inventory previously unavailable at scale, while opening OptimizeRx to the broader programmatic market, estimated at 90% of total U.S. digital display ad spend and helping DSPs pursue a share of the $19B+ pharma digital ad market.
OptimizeRx (Nasdaq: OPRX) published its 2026 Environmental, Social and Governance (ESG) report on April 29, 2026. Highlights include the appointment of Mary Varghese Presti to the board as an independent director and the first-time inclusion of Scope 3 supply chain emissions in its greenhouse gas reporting.
The report emphasizes alignment of the company’s mission with corporate responsibilities and expands governance and emissions disclosure since reporting began in 2022.
OptimizeRx (Nasdaq: OPRX) will hold a conference call on May 12, 2026 at 4:30 p.m. Eastern Time to discuss first-quarter results for the period ended March 31, 2026. Financial results will be released in a press release prior to the call.
Access details: toll-free and international dial-in numbers, Conference ID 13760191, a Call Me link, and a webcast are provided. A replay will be available for 12 months on the company investor website.
Myomo (NYSE American: MYO) appointed William "Will" Febbo to its board effective April 14, 2026, to serve until the 2028 annual meeting of stockholders, bringing the board to six directors.
Febbo has 30+ years of healthcare, financial services and technology experience, recently joined Performance Health Systems in February 2026, and previously grew OptimizeRx revenue from $5M to $92M with a five-year CAGR of 41%.
OptimizeRx (Nasdaq: OPRX) appointed Mary Varghese Presti to its Board of Directors effective April 8, 2026. Varghese Presti brings more than 25 years of healthcare, life sciences, and technology experience, including leadership at Microsoft Health & Life Sciences and hands-on M&A integration expertise.
Her appointment supports the company’s board refresh and management’s stated shift toward a more integrated, product-led platform with increasing recurring and subscription-based revenue.
OptimizeRx (Nasdaq: OPRX) reported strong 2025 results with full-year revenue of $109.4M (up 19% YoY) and adjusted EBITDA of $24.3M. Q4 revenue was $32.2M and Q4 adjusted EBITDA hit a record $12.0M. GAAP net income for 2025 was $5.1M.
The board authorized a $10M share repurchase program effective March 12, 2026, and updated 2026 guidance to $109–$114M revenue and $21–$25M adjusted EBITDA.
OptimizeRx (Nasdaq: OPRX) reported strong Q4 and full-year 2025 results with Q4 revenue $32.2M, full-year revenue $109.4M (19% YoY), and record Q4 net income $5.0M and Q4 adjusted EBITDA $12.0M. The board authorized a $10M share repurchase program and 2026 guidance was set to $109M–$114M revenue and $21M–$25M adjusted EBITDA.
Cash was $23.4M at year-end, operating cash flow improved, and the company reduced term loan principal by $2M.